Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Boeckhaus

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Kidney Journal|May 5, 2025
Urinary peptide signature distinguishes autosomal recessive polycystic kidney disease from other causes of chronic kidney diseaseKathrin Burgmaier, Bénédicte Buffin-Meyer, Julie Klein, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 15, 2026
Albuminuria drives hyperlipidemia in patients with Alport syndromeOliver Gross, Annika Jens, Agne Cerkauskaite-Kerpauskiene, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 9, 2024
Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT AlportOliver Gross, Jan Boeckhaus, Lutz T Weber, et al.
Pediatric Nephrology (Berlin, Germany)|November 22, 2025
High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometryJan Boeckhaus, Burkhard Tönshoff, Lutz T Weber, et al.
Cells|May 13, 2023
Ratio of Urinary Proteins to Albumin Excretion Shifts Substantially during Progression of the Podocytopathy Alport Syndrome, and Spot Urine Is a Reliable Method to Detect These Pathologic ChangesJan Boeckhaus, Lea Mohr, Hassan Dihazi, et al.
Kidney International Reports|May 7, 2026
German Clinical Practice Guideline on Microhematuria in Children and Young Adults: Evaluating Early Detection of Kidney DiseaseKay Latta, Jan Boeckhaus, Ina Weinreich, et al.
Clinical Genetics|October 11, 2020
Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the EARLY PRO-TECT Alport trialJan Boeckhaus, Julia Hoefele, Korbinian M Riedhammer, et al.
Pediatric Nephrology (Berlin, Germany)|February 4, 2025
Urinary Dickkopf-related protein 3 as a novel biomarker for kidney function decline in children with Alport syndromeJan Boeckhaus, Burkhard Tönshoff, Lutz T Weber, et al.
Kidney International|April 18, 2020
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndromeOliver Gross, Burkhard Tönshoff, Lutz T Weber, et al.
Kidney International Reports|December 19, 2024
SGLT2-Inhibition in Patients With Alport SyndromeJan Boeckhaus, Daniel P Gale, James Simon, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Kidney Journal|May 5, 2025
Urinary peptide signature distinguishes autosomal recessive polycystic kidney disease from other causes of chronic kidney diseaseKathrin Burgmaier, Bénédicte Buffin-Meyer, Julie Klein, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 15, 2026
Albuminuria drives hyperlipidemia in patients with Alport syndromeOliver Gross, Annika Jens, Agne Cerkauskaite-Kerpauskiene, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 9, 2024
Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT AlportOliver Gross, Jan Boeckhaus, Lutz T Weber, et al.
Pediatric Nephrology (Berlin, Germany)|November 22, 2025
High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometryJan Boeckhaus, Burkhard Tönshoff, Lutz T Weber, et al.
Cells|May 13, 2023
Ratio of Urinary Proteins to Albumin Excretion Shifts Substantially during Progression of the Podocytopathy Alport Syndrome, and Spot Urine Is a Reliable Method to Detect These Pathologic ChangesJan Boeckhaus, Lea Mohr, Hassan Dihazi, et al.
Kidney International Reports|May 7, 2026
German Clinical Practice Guideline on Microhematuria in Children and Young Adults: Evaluating Early Detection of Kidney DiseaseKay Latta, Jan Boeckhaus, Ina Weinreich, et al.
Clinical Genetics|October 11, 2020
Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the EARLY PRO-TECT Alport trialJan Boeckhaus, Julia Hoefele, Korbinian M Riedhammer, et al.
Pediatric Nephrology (Berlin, Germany)|February 4, 2025
Urinary Dickkopf-related protein 3 as a novel biomarker for kidney function decline in children with Alport syndromeJan Boeckhaus, Burkhard Tönshoff, Lutz T Weber, et al.
Kidney International|April 18, 2020
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndromeOliver Gross, Burkhard Tönshoff, Lutz T Weber, et al.
Kidney International Reports|December 19, 2024
SGLT2-Inhibition in Patients With Alport SyndromeJan Boeckhaus, Daniel P Gale, James Simon, et al.
Pageof 2